Share this guide:LinkedInXBlueskyEmail
Back to Blog
Grant Writing Tips•November 5, 2026•9 min read

Write for Your Advocate: How to Draft an NIH Application Reviewers Can Defend in the Room

You won't be at the study section meeting. Your application will be, represented by three people who read it a few weeks earlier, alongside a stack of others. What they say in those few minutes depends heavily on what you handed them. Most of us write for a careful reader. It's worth also writing for a tired one who needs to speak out loud.

What Actually Happens When Your Application Is Discussed

The mechanics vary by study section and chair, so treat what follows as the common pattern rather than a rule. The scientific review officer calls your application. The assigned reviewers state their preliminary scores. One of them, usually the first reviewer, summarizes the project and walks through strengths and weaknesses. The others add what they agree with and what they'd push back on. The chair opens the floor, and then everyone votes, with the assigned reviewers' range anchoring the scores.

Notice what that means. Panelists who weren't assigned your application may have skimmed it, or may not have opened it at all. For them, your application is whatever the assigned reviewers say it is, plus whatever gets asked in the room. Nobody reads your Approach aloud. They paraphrase it, and they paraphrase the version they can hold in their heads.

I've sat on panels where a strong application lost points because the lead reviewer couldn't explain in a sentence why the second aim was necessary. The aim was fine. The explanation just wasn't on the page in a form anyone could repeat. That's a fixable problem, and it's on the writer.

Build a One-Sentence Takeaway Reviewers Can Repeat

Before you write anything else, draft the sentence you'd want your lead reviewer to say at the start of the discussion. Something like: "This team proposes to test whether X drives Y in Z patients, using a model they built, and if it works, clinicians will have a measurable marker they don't have today." If you can't write that sentence, the reviewer can't either, and they'll fill the gap with their own framing, which may not be yours.

Then make sure that sentence, or something close to it, appears in three places: the project summary, the end of the first paragraph of Specific Aims, and the opening of Significance. Repetition feels redundant to you because you know the project. To a reviewer assembling a critique at 11 p.m. from notes on six applications, it's a landmark. For a deeper look at the page where this sentence lives, see our guide to structuring the Specific Aims page.

Write Quotable Sentences, Not Just Correct Ones

A correct sentence is accurate. A quotable sentence is accurate and self-contained, so a reviewer can lift it into their critique without needing the surrounding paragraph. Compare these two versions of the same claim.

Same claim, two drafts

Correct: "As described above, the approach has been shown to work in this context, which supports its use here."

Quotable: "We have run this assay on 40 patient samples and it separated responders from non-responders; Aim 2 applies the same assay to an independent cohort."

The second one carries its own evidence and its own link to the next step. A reviewer can say it nearly verbatim.

Practical habits help. Lead each paragraph with its claim instead of ending on it. Put the number next to the noun. Name the specific cohort, model, or dataset instead of "our established system." And watch pronouns that point back across a page break; "this" and "these" are fine in a draft and risky in a sentence someone has to read out of context.

One caution. Quotable doesn't mean punchy for its own sake. Reviewers have heard every superlative there is, and a paragraph of confident adjectives reads as a lack of data. Concrete beats clever.

Pre-Answer the Three Criticisms You Already Know Are Coming

Every application has weak points, and you usually know where yours are. Maybe the sample size is modest. Maybe Aim 3 depends on a reagent you haven't validated yet. Maybe the team has no one with experience in the clinical side. Reviewers will find these. The question is whether the answer is already on the page when they do.

List your three most likely criticisms, honestly, then give each a short, direct answer where the reviewer will be looking: in the Approach, under a heading like "Potential problems and alternatives," or in a sentence right after the claim that raises the concern. The tone matters. A defensive paragraph sounds like worry. A calm one ("If recruitment lags, we'll add the second site, which has agreed in writing") sounds like a plan.

What goes wrong

The weakness is buried, vague, or admitted without a mitigation. A reviewer who finds a problem you didn't acknowledge assumes you didn't see it. A reviewer who finds one you acknowledged and addressed often just writes "adequately addressed" and moves on.

I can't promise this changes a score by any particular amount, and nobody publishes that number. What I can say is that the discussion tends to go better when the concern and the answer are in the same place, because the reviewer can read both at once.

A Practical Test: The Two-Minute Read-Aloud

Ask a colleague in an adjacent field to read your Specific Aims and Significance, close the file, and then do what your lead reviewer will do: summarize the project out loud in about two minutes, then name the two biggest weaknesses. Record it, or take notes without interrupting.

Compare what you hear to what you intended. Anything they skip is probably buried. Anything they get wrong is probably ambiguous. Any weakness they name that you didn't pre-answer goes straight onto your revision list. This is a lighter-weight cousin of a full mock study section, and it's something you can do in an afternoon when a full mock isn't feasible.

Do it twice, with different people, because one reader's blind spot is often your own.

Frequently Asked Questions

Do all NIH applications get discussed at the study section meeting?

No. Applications in the lower-scoring portion of a panel's assigned set may be designated as not discussed, and the exact process depends on the study section and current NIH review policy. Check the most recent NIH guidance and your scientific review officer for how this applies to your panel. Either way, the written reviews your assigned reviewers submit before the meeting matter just as much as the live discussion.

Should I write differently for assigned reviewers and the rest of the panel?

You can't target them separately, but you can layer the document. Put the clear, repeatable version on the first page and in the summary statements of each section. Put the technical depth below, where the assigned specialist will go looking for it.

Is it risky to name weaknesses in my own application?

Naming a weakness without an answer is risky. Naming one with a concrete mitigation usually reads as maturity. Stick to weaknesses a competent reviewer would find anyway, and keep each one short.

Can I contact my reviewers to explain the application?

No. Contacting reviewers about an application under review is inappropriate and can cause real problems. Your channel to them is the application itself. If you have questions about process, talk to the scientific review officer or your program officer, and see our guide on SRO outreach.

Ground Your One-Sentence Takeaway in Real Funding Data

A takeaway lands harder when it's anchored to what NIH is actually funding. Check recent award patterns for your topic, see which institutes fit your project, and find investigators working nearby.

Trust & Transparency

How this content is reviewed before it goes live

NIH Grant Explorer combines public NIH records with editorial interpretation. We publish the review structure, methodology, and correction pathways so readers can judge the value of a guide or chart for themselves.

When a topic turns into an official policy question, we point readers back to NIH rather than pretending an independent site can replace the underlying federal guidance.